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Nef deletion mutants of SIV-expressing interleukin-4 (SIV-IL4) or interferon- (SIV-IFN) were constructed to study the effect
of interferon- (IFN-) and interleukin-4 (IL-4) on viral load, immunogenicity, and protective properties. Four rhesus monkeys
were infected with SIV-IL4 and four were infected with SIV-IFN. During the acute phase of infection, the cell-associated viral
load, but not the plasma viral RNA load, was approximately 10-fold lower in SIV-IFN-infected macaques than in SIV-IL4-
infected rhesus monkeys. The viral load declined to hardly detectable levels 4 months postinfection in all animals. SIV
antibody titers and the affinity of these antibodies were higher in SIV-IL4-infected macaques than in SIV-IFN-infected animals,
consistent with a stimulation of T helper cell type 2 immune responses by IL-4. At peak viremia, there was a trend to higher
interleukin-12 and perforin mRNA levels of the lymph nodes in the SIV-IFN-infected macaques than in the SIV-IL4-infected
monkeys. Deletion of the viral IFN gene, but not the viral IL-4 gene, after the development of antiviral immune responses
suggests a repressive effect of IFN, but not IL-4, on virus spread in vivo. A trend to higher set point viral RNA levels in
SIV-IL4-infected monkeys in comparison to monkeys infected with the parental nef deletion mutant and similar viral RNA
levels during the acute phase of infection suggest that IL-4 expression leads to a slight reduction in the control of virus
replication by host immune responses. However, SIV-IL4 and SIV-IFN induced protection against a homologous challenge
virus. Subsequent challenge with an SIV-HIV-1 hybrid virus (SHIV) also revealed protection in the absence of neutralizingKey Words: HIV; vaccine; cytokines.
INTRODUCTION
Live-attenuated immunodeficiency viruses such as nef
deletion mutants of SIV are effective vaccines in the
SIV-macaque model (reviewed in Desrosiers, 1996; John-
son, 1999). They can induce protection against patho-
genic homologous and heterologous viruses after intra-
venous or mucosal challenge. However, safety still is the
predominant concern for the use of live-attenuated im-
munodeficiency viruses in humans. During primary infec-
tion, nef deletion mutants of SIV replicate to substantial
titers and some infected monkeys develop AIDS at later
time points (Baba et al., 1999). Progression to AIDS after
infection with nef deletion mutants is also frequently
observed in newborn monkeys (Baba et al., 1995; Wyand
et al., 1997). Therefore, further attenuation would be re-
quired for a potential application in humans. However,
further attenuation might be limited, since the protective
1 To whom correspondence and reprint requests should be ad-
dressed at Department of Molecular and Medical Virology, Ruhr-Uni-473properties of the attenuated vaccines seem to correlate
with their replicative capacity (Lohman et al., 1994;
Wyand et al., 1996; Johnson et al., 1999). To increase the
immunogenicity of live-attenuated vaccines, we previ-
ously immunized monkeys with a nef deletion mutant of
SIV expressing the broadly immunostimulating cytokine
interleukin-2 (IL-2) (Gundlach et al., 1997, 1998). Although
the IL-2-producing vaccine induced solid protection
against subsequent challenge, IL-2 expression seemed
to increase viral load during primary infection. In con-
trast, monkeys infected with an interferon- (IFN-) pro-
ducing nef-deletion mutant had reduced cell-associated
viral loads, while still being protected from subsequent
challenge (Giavedoni et al., 1997). By increasing the
immunogenicity without enhancing viral load, the expres-
sion of immunostimulatory cytokines by live-attenuated
immunodeficiency virus vaccines might increase the
window of opportunity between safe, but ineffective, and
effective, but unsafe, vaccines.
The mechanisms mediating protection induced by
live-attenuated immunodeficiency virus vaccines are stillantibodies. © 2003 Elsevier Science (USA)
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doi:10.1006/viro.2002.1763a matter of debate. Recent studies indicate a strong
induction of cellular immune responses (Dittmer et al.,
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1995; Johnson et al., 1997; Gauduin et al., 1999). Since the
control of the wild-type virus is affected by depletion of
CD8 cells (Schmitz et al., 1999), it is expected that these
cells also play an important role for protection from
challenge after vaccination with attenuated viruses by
either lytic or nonlytic mechanisms (Gauduin et al., 1998).
By using various challenge viruses, it was shown that
protection can be observed in the absence of neutraliz-
ing antibodies (Quesada-Rolander et al., 1996; Shibata et
al., 1997; Bogers et al., 1995; Dunn et al., 1997; Miller et
al., 1997; Lewis et al., 1999; Wyand et al., 1999), receptor
interference phenomena, or chemokine inhibition (Gund-
lach et al., 1998). However, this does not exclude the
possibility that neutralizing antibodies contribute to pro-
tection after vaccination with live-attenuated immunode-
ficiency virus vaccines. In the present study, we at-
tempted to modulate the antiviral immune responses
induced by live-attenuated vaccines into either a
T-helper cell type-1 (Th1) or a type-2 (Th2) immune re-
sponse by infecting monkeys with an IFN-- or interleu-
kin-4- (IL-4) expressing nef deletion mutant of SIV, re-
spectively, and analyzed the consequences for vaccine
protection.
Immunomodulatory approaches have also been pro-
posed to complement anti-retroviral chemotherapy in
HIV-1-infected patients. Depending on the stage of HIV
infection, different strategies such as (i) inhibition of virus
replication, (ii) restoration of cell-mediated immune re-
sponses, (iii) immunosuppression to prevent virus
spread in activated T-cells or macrophages, or (iv) induc-
tion of HIV-1 in latently infected T cells and macrophages
to increase the susceptibility to anti-retroviral therapy
and antiviral immune responses have been discussed
(reviewed in Pantaleo, 1997). Cytokines are the main
effector or target molecules by which such immuno-
modulation can potentially be achieved. Therefore, the
effect of cytokines on HIV replication has been exten-
sively studied mostly in cell culture. Depending on the
cytokine and the cell type studied, cytokines can have
profound effects on virus replication (reviewed in Mat-
suyama et al., 1991; Poli and Fauci, 1993). In primary T
cells, IL-4 was shown to increase replication of syncytia-
inducing HIV-1 coinciding with up regulation of CXCR4
expression (Wang et al., 1998; Valentin et al., 1998; Galli
et al., 1998). Replication of non-syncytia-inducing HIV-1
and CCR5 expression was reduced by IL-4 treatment,
although IL-4 increased viral transcription in T cells in-
dependent of coreceptor usage (Valentin et al., 1998). In
monocyte-derived macrophages the opposite effect of
IL-4 on viral transcription and replication was observed
depending on the state of differentiation (Schuitemaker
et al., 1992; Naif et al., 1997). In macrophages from
rhesus monkeys IL-4 was shown to enhance replication
of a SIV-HIV-1 hybrid virus (Buch et al., 2001). Opposite
effects on HIV-1 replication have also been reported for
IFN-. In T cells IFN- increased HIV-1 replication (Vy-
akarnam et al., 1990), whereas it was either inhibitory or
stimulatory in macrophages (Koyanagi et al., 1988; Korn-
bluth et al., 1989). Inhibition of Tat-transactivation, up
regulation of CCR5 or C-C chemokines, and down regu-
lation of CD4 have been proposed as molecular mech-
anisms for the bidirectional effects (Emilie et al., 1992;
Hariharan et al., 1999). Opposite effects of IFN- depend-
ing on the type of infected cells were also observed in
rhesus monkey cells (Buch et al., 2001). In addition to
these direct effects of cytokines on virus replication,
modulation of the antiviral immune response by cyto-
kines might further effect the course of infection in vivo.
Up regulation of MHC-I and MHC-II by IFN- might for
example increase the induction of antiviral immune re-
sponses. Due to these pleiotropic effects of cytokines, it
is difficult to predict their in vivo activity based on in vitro
data. Therefore, we did not only analyze the effect of
IFN- and IL-4 on vaccine protection but also studied the
effect of IFN- and IL-4 on virus replication in rhesus
monkeys.
RESULTS
Construction and in vitro characterization of SIV-IL4
and SIV-IFN
Yilma and colleagues observed that inserting the human
IFN- cDNA in place of nef of SIV yielded a IFN--producing
virus, which was unstable in cell culture and rhesus mon-
keys (Giavedoni and Yilma, 1996; Giavedoni et al., 1997).
The increase in length of the viral genome, an inhibitory
effect of IFN- on virus replication, and/or an immune re-
sponse to the human IFN- protein in rhesus monkeys,
could lead to the outgrowth of viruses with deletions in the
inserted IFN- gene. To overcome some of these limita-
tions, the coding region of IL-4 and IFN- were amplified
from the cDNA of stimulated peripheral blood mononuclear
cells (PBMC) from rhesus monkeys. Sequence analyses
revealed differences to the previously published sequence
of rhesus monkey IL-4 and IFN- as described under Ma-
terials and Methods. The PCR products were cloned into a
proviral clone of SIVmac239 (SIVNU) (Gundlach et al.,
1997), in which a total of 513 bp had been deleted in nef and
the U3 region (Fig. 1). The overall length of the IL-4 or IFN-
cDNA-containing viruses (SIV-IL4, SIV-IFN) was shorter
than wild-type virus which should contribute to the stability
of the virus. After transfection of proviral DNA of the cyto-
kine-containing constructs into CEMx174 cells, replication-
competent viruses were obtained. In the supernatant of
infected cells, 100 units IL-4/ml and 500 units IFN-/ml were
detected, indicating efficient expression of both cytokines.
To study the stability of the constructs, SIV-IL4 and SIV-IFN
were passaged six times, as previously described (Gund-
lach et al., 1997). Both viruses maintained a full-length
cytokine gene and expressed bioactive cytokines for the
entire duration of the passage experiment (Fig. 2). To de-
termine the effect of the cytokines on virus replication in cell
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culture, stimulated PBMCs from rhesus monkeys were in-
fected in two independent experiments with the parental
nef deletion mutant SIVNU, SIV-IL4, SIV-IFN, or SIV-
mac239. Only minor differences were observed in the rep-
lication kinetics (Fig. 3). Therefore, production and secretion
of IL-4 or IFN- by the infected cell did not affect virus
replication notably.
Infection of rhesus monkeys
Subsequently, four rhesus monkeys each were intra-
venously infected with 300 tissue culture infectious dose
(TCID50) of SIV-IL4 or SIV-IFN. The cell-associated viral
load in the SIV-IL4-infected monkeys was similar to the
viral load previously observed (Gundlach et al., 1998) in
monkeys infected with SIVNU (Figs. 4A and 4C). In
contrast, during the first 2 months after infection, the
cell-associated viral loads in SIV-IFN-infected macaques
were significantly lower than in SIVNU- and SIV-IL4
infected monkeys (Figs. 4 B and 4C; t test: P  0.05).
Three to four months postinfection, the cell-associated
viral load had declined to hardly detectable levels in both
groups. Determination of the viral RNA load revealed
very similar RNA levels during the first 2 months after
infection with SIV-IL4 or SIV-IFN (Figs. 4D and 4E). They
were in a similar range as the RNA levels of SIVNU-
infected monkeys and 100-fold lower than in SIVmac239-
infected animals (Fig. 4F). Mean set point RNA levels 4
months postinfection were 40-fold higher in the SIV-IL4-
infected monkeys than in the SIVNU-infected animals
(Fig. 4F), but this difference did not reach statistical
significance (t test: P  0.063).
To analyze whether the repressive effect of IFN- on
the cell-associated viral load would lead to the deletion
of the IFN- cDNA from the viral genome, isolates were
recovered from PBMCs at different time points after in-
fection. Characterization of the isolates from the SIV-IFN-
infected monkeys by PCR with primers, flanking the in-
serted cytokine gene, revealed deletions in the IFN-
cDNA beginning 12 weeks postinfection (Fig. 5B). Cyto-
kine activities were also determined in the supernatant
of CEMx174 cells infected with the virus isolates. Pro-
duction of bioactive IFN- by the isolates was already
absent 8 weeks postinfection in some animals (8316-IFN,
8317-IFN). Reappearance of the full-length IFN- cDNA in
monkey 8316-IFN at 16 weeks postinfection might be due
to the low viral load at this time point leading to the
isolation of virus from only one or very few infected cells.
All virus isolates from the SIV-IL4-infected monkeys con-
tained a full-length IL-4 cDNA and produced bioactive
IL-4 (Fig. 5A), indicating a selective pressure against
IFN- but not IL-4 expression.
Determination of cytokine mRNA expression
Cytokine mRNA levels were determined in the lymph
nodes of the monkeys 2 weeks postinfection (Fig. 6) to
FIG. 1. Map of SIV-IL4 and SIV-IFN. Deleted regions are marked by shaded boxes with the first and last deleted nucleotide given after the “‚” sign
(numbering according to GenBank entry M33262). The inactivated nef reading frame is marked in black. IL4: coding region (462 bp) of rhesus monkey
interleukin-4; IFN: coding region (498 bp) of rhesus monkey interferon-.
FIG. 2. Stability of SIV-IL4 (A) and SIV-IFN (B) in cell culture. SIV-IL4
and SIV-IFN were passaged on CEMx174 cells for the indicated times.
The size of the inserted cytokine cDNA was determined by PCR with
primers flanking the insertion site at the indicated number of passages.
The amount of bioactive cytokine in the supernatant of infected cells
was determined in parallel. : 25 U IL-4/ml (A) and 25 U IFN-/ml
(B); : 2.5 U IL-4/ml (A) and 2.5 U IFN-/ml (B).
475IMMUNOMODULATING LIVE-ATTENUATED SIV
study the consequences of virally expressed cytokines
on the cytokine network in vivo. IFN- mRNA levels were
similar in both groups. Endogenous IFN- mRNA levels
of the lymph nodes were probably too high to reveal
virally expressed IFN- in approximately 1 infected of
1000 uninfected cells. IL-4 mRNA could only be detected
in the lymph nodes of monkeys infected with SIV-IL4.
Subsequent analyses with primers only present on the
endogenous rhesus IL-4 transcript revealed that the IL-4
mRNA levels were predominantly virally expressed and
not cellularly expressed (data not shown). Perforin mRNA
levels as a marker for activated CTLs and IL-12 mRNA
levels were higher in the SIV-IFN-infected macaques,
while macrophage inflammatory protein-1 transcripts
seemed to be higher in SIV-IL4-infected monkeys. How-
ever, these differences did not reach statistical signifi-
cance (Fig. 6).
Follow-up of immunological parameters
To analyze whether cytokine expression would alter
antiviral immune response, antibody titers were deter-
mined at different time points after infection. Higher an-
tibody titers against whole-virus antigen were found in
SIV-IL4-infected macaques compared to SIV-IFN-infected
macaques (Figs. 7A and 7B; t test: P  0.032). Using a
recombinant SIV Env protein ELISA, the SIV Env antibod-
ies also had a higher affinity in the SIV-IL4 group than in
the SIV-IFN group at 22 weeks postinfection (Fig. 7C).
These results are consistent with a modulation of anti-
viral immune response by IL-4 or IFN- toward a Th2 or
Th1 immune response, respectively.
To assess the cellular immune response, the SIV-
specific T helper cell proliferation was determined. As
observed previously in monkeys infected with nef dele-
tion mutants of SIV, SIV-specific T helper cell proliferation
could be detected repeatedly, but was rather weak. No
differences were observed between the two groups
(data not shown).
Phenotypic characterization of PBMCs
PBMCs were characterized phenotypically to further
assess the consequence of infection with SIV-IL4 or
SIV-IFN for suppression or activation of the immune
system. As already suggested by the low viral load, all
animals were asymptomatic during the observation pe-
riod. The percentage of CD29CD4 cells of total lym-
phocyte counts was determined, since a drop in this
population is an early prognostic marker for a decline in
immune function in humans (Blatt et al., 1995; Dolan et
al., 1995) and macaques (Kneitz et al., 1993; Morphey-
Corb et al., 1989). No reduction was observed in any of
the macaques (Fig. 8A). The activation of CD8 cells was
monitored by analysis of the percentage of CD69 cells
among CD8 cells. This cell population remained rather
unchanged during the first 3 months after infection in
three of the SIV-IL4-infected macaques. Strong activation
of CD8 cells was observed in the fourth SIV-IL4-infected
monkey (8315-IL4, Fig. 8B). Eight to twelve weeks postin-
fection the percentage of CD69 CD8 cells had nearly
doubled in three of the SIV-IFN-infected animals and
declined thereafter close to preinfection values (Fig. 8B).
Further phenotypic characterization of the PBMCs re-
vealed an increase in the percentage of B cells, which
might be slightly more pronounced in the SIV-IL4-in-
fected macaques than in the SIV-IFN-infected macaques
(Fig. 8C).
Challenge of vaccinated macaques
The consequences of IL-4 or IFN- expression by
live-attenuated immunodeficiency viruses for vaccine
protection were analyzed by intravenous challenge with
FIG. 3. Replication properties of SIV-IL4 and SIV-IFN in PBMCs. Stimulated rhesus PBMCs were infected with SIV-IL4, SIV-IFN, SIVNU, or wild-type
SIVmac239 (SIVwt) after normalization for reverse transcriptase activity. Virus replication was monitored by measuring reverse transcriptase activity
in the supernatant of infected PBMCs. Results from two different blood donors are shown. PSL: relative photon-stimulated luminescence.
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100 monkey infectious doses (MID50) of homologous SIV-
mac239. Two naive control monkeys infected in parallel
with the challenge virus developed high viral loads. Sim-
ilar high levels were reached in the SIV-IL4-infected
animal (8158-IL4), which had the highest viral load prior
to challenge. The other three SIV-IL4-infected macaques
maintained low viral load levels (Fig. 9). In contrast, a
transient increase in viral load was observed in all SIV-
IFN-infected macaques. Two months after challenge the
viral load declined to approximately 1000-fold lower lev-
els than in the naive control monkeys infected in parallel
(Fig. 9). Characterization of virus isolates by PCR re-
vealed challenge virus sequences in three of the SIV-
IFN-infected macaques (Fig. 9). In contrast, the challenge
virus could only be detected in one of the SIV-IL4-in-
fected monkeys (8158-IL4) which developed a reduced
percentage of CD29CD4 lymphocytes after challenge
(data not shown) in the presence of a high viral load. The
FIG. 4. Cell-associated viral load (A–C) and viral RNA levels (D–F) in monkeys infected with SIV-IL4 (A, D) and SIV-IFN (B, E). C and F give the mean
viral load of four SIV-IL4-, SIV-IFN-, SIVNU-, or wild-type SIVmac239 (SIVwt)-infected macaques. Data from SIVNU-infected monkeys have been
previously published (Gundlach et al., 1997).The four-digit numbers are monkey designations and are followed by an abbreviation of the virus they
were infected with: IL4: SIV-IL4; IFN: SIVIFN. The asterisk in (C) indicates a time point at which the end point of the limiting dilution coculture had
not been reached in some SIVNU-infected macaques.
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data suggest that this singular SIV-IL4-infected monkey,
which did not have a sterilizing immunity, was unable to
contain the challenge virus. In contrast, at least three of
the SIV-IFN-infected monkeys controlled replication of
the challenge virus even in the absence of a sterilizing
immunity.
Three monkeys of each group were subsequently re-
challenged with an SHIV virus, in which the env gene of
SIV had been replaced by the env gene of HIV-1
(Reimann et al., 1996a,b). Since it was previously shown
that antibodies against SIV-Env neither cross-react with
HIV-1 Env nor neutralize HIV-1 (Bogers et al., 1995; Shi-
bata et al., 1997; Lewis et al., 1999), the relevance of
antibodies against Env for protection induced by SIV-IL4
or SIV-IFN could be determined. Both groups of vacci-
nated macaques had reduced viral loads in comparison
to two naive control monkeys infected in parallel (Fig. 10).
Virus could be isolated at the time of necropsy from
different lymphatic tissues. Characterization of the iso-
lates by PCR revealed the SHIV challenge virus in two of
the SIV-IL4 immunized monkeys (8157-IL4, 8312-IL4), but
in none of the SIV-IFN immunized monkeys (Table 1). The
SIV challenge virus was isolated from the monkeys 8157-
IL4, 8149-IFN, and 8317-IFN. In two monkeys (8315-IL4,
8147-IFN) only the vaccine viruses but neither of the
challenge viruses could be detected. Therefore, mon-
keys vaccinated with SIV-IL4 or SIV-IFN were able to
contain replication of the SHIV challenge virus even in
the absence of Env-specific neutralizing antibodies.
DISCUSSION
The effect of an Th1 and Th2 inducing cytokine on
replication and immunogenicity of SIV was determined
by expressing the cDNAs for IFN- and IL-4 instead of
the nef gene of SIV, respectively. A total of 513 bp had
been deleted from the nef gene, to avoid increasing the
overall length of the viral genome. The SIV-IL4 and the
SIV-IFN virus were stable in cell culture for at least six
passages, as previously observed for an IL-2-producing
SIV (Gundlach et al., 1997). Neither IL-4 nor IFN- af-
fected virus replication on CEMx174 cells (data not
shown) or stimulated PBMCs. A very similar construct
containing human IFN- in place of a 186-bp deletion of
nef had developed deletions after three passages in cell
culture (Giavedoni and Yilma, 1996). Since the replication
of this construct was reduced in stimulated PBMCs to a
similar degree as a control virus containing the IFN- in
antisense orientation, much of the instability of the
FIG. 5. Stability of SIV-IL4 (A) and SIV-IFN (B) in rhesus monkeys. The presence of the IL-4 and IFN- coding region in isolates recovered at the
indicated time points after infection was determined by PCR using primers flanking the inserted cytokine cDNA. The amount of bioactive cytokine in
the supernatant of infected cells was measured in parallel. : 25 U/ml IL-4 (A) and 25 U/IFN-/ml (B); : 2.5 U IL-4/ml (A) and 2.5 U IFN-/ml.
(B). Wpi: weeks post infection; SIVwt: DNA from SIVmac239-infected CEMx174 cells was analyzed by PCR; neg.: DNA from uninfected CEMx174 cells
was used.
FIG. 6. Cytokine mRNA levels in the lymph nodes of monkeys 2
weeks after infection. The mean and the standard deviation are shown
for SIV-IL4- and SIV-IFN-infected monkeys. The numbers above the
columns give the P value of the t test comparing the paired columns.
Perf: perforine; MIP-1: macrophage inflammatory protein-1.
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former study in cell culture seems to be due to the
increased size of the viral genome.
Despite the stability of our SIV-IFN in cell culture, we
noticed deletions in isolates from three of four SIV-IFN-
infected monkeys starting 12 weeks postinoculation.
Loss of bioactive IFN- production preceded the occur-
rence of the deletions indicating that there is a selective
pressure against the expression of IFN- and not only a
selection for viruses with a reduced genome size. This
conclusion is supported by the stability of the SIV-IL4
virus, which has a similar genome size.
Consistent with a selective pressure against viral IFN
expression, cell-associated viral loads were reduced
during primary infection with SIV-IFN, as reported previ-
ously (Giavedoni et al., 1997). Surprisingly, the amount of
viral RNA in the plasma, which is mainly derived from
viruses produced in the lymphatic tissues, was similar
during the acute phase of infection in SIV-IFN-, SIV-IL4-,
and SIVNU- (Gundlach et al., 1997) infected monkeys.
Since infected PBMCs contribute little to virus production
as determined by plasma viral RNA levels (Wei et al.,
1995), the reduced cell-associated viral load in SIV-IFN-
infected monkeys might be due to a change in the hom-
ing properties of SIV-IFN-infected PBMCs rather than
due to a decrease in virus replication. A trend to higher
set point viral RNA levels was observed in SIV-IL-4-
infected monkeys in comparison to SIVNU-infected
monkeys (Gundlach et al., 1997). Since RNA levels were
similar in both groups during the acute phase of infec-
tion, this suggests that IL-4 slightly reduces control of
virus replication by the host immune response rather
than increasing virus replication.
Previous work showing high levels of IL-4 mRNA in
lymph nodes of SIVmac239- but not SIVmac239nef-
infected monkeys raised the possibility of a direct con-
tribution of IL-4 to the pathogenicity of the wild-type virus
(Zou et al., 1997). It has also been shown in infected
rhesus monkeys that induction of a Th2 cytokine milieu
characterized by the presence of IL-4 mRNA, but not
IFN- mRNA, favored immunodeficiency virus replication
in tissue macrophages (Buch et al., 2001). However, the
low viral load levels in SIV-IL4-infected animals com-
pared to monkeys infected with pathogenic wild-type
virus indicate that IL-4 itself is not sufficient to consider-
ably enhance the pathogenic properties of nef-deletion
mutants of SIV. This is in sharp contrast to results from
experiments with a recombinant ectromelia virus ex-
pressing IL-4, which seemed to suppress primary anti-
viral cell-mediated immune responses and which in-
duced mousepox in genetically resistant mice (Jackson
et al., 2001).
The analysis of the cytokine network in the lymph
nodes of infected monkeys revealed a trend to higher
IL-12 and perforin mRNA in SIV-IFN-infected monkeys in
comparison to SIV-IL4-infected animals. In the SIV-IL4-
infected animals, higher antibody titers were observed
as previously seen in monkeys vaccinated with DNA
against SIV in the presence of IL-4 (Boyer et al., 2002).
These results are consistent with a polarizing effect of
IFN- and IL-4 toward Th1 and Th2 immune responses,
respectively. After challenge with the homologous virus,
different patterns of protection seemed to emerge in the
SIV-IL4- and the SIV-IFN-infected monkeys. In three of
four SIV-IL4-infected monkeys, viral load remained rather
low after challenge, and the challenge virus could not be
detected. In the SIV-IFN-infected monkeys a transient
increase in viral load was observed, which was due to
the challenge virus in three of the four animals. While the
SIV-IL4-infected monkey, in which the challenge virus
could be detected, developed a high viral load rapidly,
the SIV-IFN-infected monkeys maintained low viral load
levels 2 months after challenge. To test the hypothesis
FIG. 7. Humoral immune response in infected macaques. Antibody
titers against whole-virus antigen in monkeys infected with SIV-IL4 (A)
or SIV-IFN (B) at different time points after infection. The four-digit
numbers in the figure legend are monkey designations as described in
the legend to Fig. 4. (C) Mean and standard deviation (in brackets) of
Env- and Gag-specific antibody levels and avidity of Env-specific anti-
bodies in plasma (dilution of 1:100) 22 weeks after infection with SIV-IL4
or SIV-IFN. RFU: relative fluorescence units; ab: antibody; *Differences
between the groups were statistically significant (P  0.05, Mann–
Whitney U test).
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that a strong humoral immune response induced in the
SIV-IL4-infected monkeys contributed to early contain-
ment of the homologous challenge virus, three monkeys
of each group were rechallenged with an SIV-HIV-1 hy-
brid virus, which is not neutralized by antibodies to SIV
Env (Bogers et al., 1995; Shibata et al., 1997; Lewis et al.,
1999). Despite that, viral load after the second challenge
was similar in the SIV-IL4- and SIV-IFN-vaccinated ma-
caques. This suggests that the SIV-IL4-induced protec-
tion against SHIV challenge did not depend critically on
neutralizing antibodies. Since the SHIV challenge virus
could only be detected in two SIV-IL4-immunized ani-
mals, SIV-IFN might induce better protection in the ab-
sence of neutralizing antibodies than SIV-IL4. However, it
should be kept in mind that due to the large variability in
monkeys infected with the same virus and the small
FIG. 8. Subpopulations of PBMC after infection with SIV-IL4 or SIV-IFN. The percentage of CD29CD4 double-positive cells of lymphocytes (A),
CD69 cells of CD8 cells (B), and CD20 cells of lymphocytes (C) was determined before and after infection. Results are expressed as percentage
of the mean of two to three preinfection values. The four-digit numbers are monkey designations and are followed by an abbreviation of the virus it
was infected with (see legend to Fig. 4).
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number of animals available for the study the differences
in protection observed between the groups did not reach
statistical significance. Therefore, a larger number of
animals is needed to determine whether the SIV-IL4 or
the SIV-IFN virus are better suited as a live-attenuated
vaccine.
MATERIALS AND METHODS
Construction of SIV-IL4 and SIV-IFN
To clone the cDNA of IL-4 and IFN- of rhesus mon-
keys, it was not possible to use the sequence deposited
in the GenBank, since primers spanning the 5 and 3
coding region of the human cDNAs had been used to
amplify the cDNAs of rhesus monkeys (Villinger et al.,
1995). Therefore, primers based on the 5 and 3 untrans-
lated regions of human IL-4 and human IFN- were first
used to amplify the respective cDNAs from Con A stim-
ulated PBMCs of rhesus monkeys. Sequencing the first
and last 10 codons of the PCR products of the rhesus
IL-4 and IFN- cDNA revealed the following differences
to the previously published sequences: rhIL4: codon 145
AAA (R) to AGA (K), codon 152 TCG (S) to CGG (R);
rhIFN: codon 3 TAT (Y) to TAC (Y), codon 165 CAG (Q) to
CAA (Q), stop codon TGA to stop codon TAA. Based on
these results the following primers were used to amplify
the cDNA of rhesus (rh) IL-4 and IFN- from Con A
stimulated PBMCs from rhesus monkeys: rhIL4s: CCGG-
GACCATGG-GTCTCACCTCCCAACT; rhIL4a: CCGGGTC-
AGCTCCGACACTTTGAAT; rhIFNs: CCGGGACCATGAAA-
TATACAA-GTTATATCTTGGCT; rhIFNa: CCGGGTTACTG-
GGA-TGCTCTTCGACCT. The PCR products were cloned
into the XmaI site of pBRmacNU as previously de-
scribed (Gundlach et al., 1997), resulting in pBRmac-IL4
and pBRmac-IFN. Sequence analyses of two indepen-
dent clones of the rhesus cytokine genes revealed se-
quence heterogeneity in comparison to the previously
published sequence at IL-4 codon 129 AGC (S) instead of
AAC (N) and IFN- codon 126 TCG instead of TCA (S).
FIG. 10. Cell-associated viral load after challenge with heterologous
virus. Fifty-nine weeks after infection with SIV-IL4 (A) and SIV-IFN (B),
monkeys were challenged intravenously with SHIV89.6P. The four-digit
numbers are monkey designations and are followed by an abbreviation
of the virus it was first infected with: IL4: SIV-IL4; IFN: SIV-IFN; SHIV:
SHIV89.6P.
FIG. 9. Cell-associated viral load after challenge with homologous
virus. Twenty-two weeks after infection with SIV-IL4 (A) and SIV-IFN (B),
monkeys were challenged intravenously with SIVmac239. Viral isolates
were characterized by PCR as described under Materials and Meth-
ods. Results of the characterization are incorporated in the figure: V:
vaccine virus; C: challenge virus. The four-digit numbers are monkey
designations and are followed by an abbreviation of the virus it was
first infected with: IL4: SIV-IL4; IFN: SIV-IFN; SIV: SIVmac239.
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Virus cultures
To generate biologically active SIVs pBRmac239,
pBRmacNU, pBRmac-IL4, or pBRmac-IFN, plasmid DNA
was transfected into CEMx174 cells by the DEAE-Dextran
method. Reverse transcriptase activity of the supernatant of
infected cells was determined as described (Potts, 1990).
As a read out for reverse transcriptase activity, the photon
stimulated luminescence (PSL) was quantitated in a phos-
phorImager. SIV-IL4 and SIV-IFN were passaged six times
by infecting 5  105 CEMx174 cells with 500 l filtered
supernatant of cultures infected with the respective virus.
Viral supernatants were harvested every 5 to 8 days as
soon as peak syncytia formation was observed. For the in
vivo experiments, viral stocks were prepared on rhesus
monkey PBMCs (U¨berla et al., 1995). The median TCID50 of
the PBMC grown virus stocks was determined in CEMx174
cells as described (Johnson and Byington, 1990). The min-
imal number of PBMCs of infected macaques required for
virus isolation in cocultures with C8166 cells was deter-
mined as a measure of cell-associated viral load (Hoch et
al., 1995).
Infection of rhesus monkeys
Animals were housed at the German Primate Center in
Go¨ttingen. Handling of the monkeys and collection of
specimens were performed according to institutional
guidelines as described previously (Stahl-Hennig et al.,
1990). Four rhesus monkeys of Indian origin (seronega-
tive for SIV, D-type retroviruses, and STLV-1) were in-
fected intravenously with 300 TCID50 of SIV-IL4, and four
animals received 300 TCID50 of SIV-IFN. All preinfected
animals were challenged intravenously 22 weeks after
infection with SIV-IL4 or SIV-IFN along with two control
monkeys with cell-free supernatant of rhesus monkey
PBMC cultures containing 100 median MID50 of patho-
genic SIVmac239 nef-open (Lewis et al., 1994). Three
monkeys of each group with low viral load levels were
rechallenged with pathogenic SHIV89.6P (Reimann et al.,
1996b) 55 weeks after the first challenge. The SHIV89.6P
original virus stock (kindly provided by Dr. Norman
Letvin) was passaged once in rhesus monkey PBMCs to
generate cell-free virus stocks. Approximately 15,000
MID50 of SHIV89.P were injected intravenously into the
vaccinated animals. Two control animals received 10-
fold less virus by the same route.
Antiviral immune responses
Antibodies to whole-virus antigen were determined as
described (Stahl-Hennig et al., 1992). Antibodies specific
for SIV Env and Gag were determined in plasma using a
fluorescence ELISA as described previously (Sopper et
al., 1998). The avidity index values of plasma antibodies
to Env were determined by measuring the stability of
antibody–Env complexes in the presence of 8 M urea by
the similar fluorescence ELISA as described previously
(Cole et al., 1997). Plasma samples were tested at differ-
ent dilutions. After incubation of the plasma in antigen-
coated microtiter plates, duplicate wells were treated in
parallel with either PBS (0.1% Tween 20) or 8 M Urea in
PBS (0.1% Tween 20). After extensive washing with PBS
the assay was continued and the avidity index was then
calculated from the ratio of the relative fluorescence
units (RFU) obtained with urea to that observed without
urea multiplied by 100. For the T cell proliferation assay,
PBMCs were stimulated with 0.25 g purified heat-inac-
tivated SIVmac251 for 7 days and [3H]thymidine incorpo-
ration was measured after a 6-h incubation period (Hoch
et al., 1995). The stimulation index was calculated from
the mean counts of triplicate wells by dividing the mean
counts of antigen-containing cultures through the mean
counts of cultures without antigen. Stimulation indices
over 2 were considered positive.
TABLE 1
Characterization of Virus Isolates
8157-IL4 8312-IL4 8315-IL4 8147-IFN 8149-IFN 8317-IFN
PBMC neg. neg. neg. neg. neg. C1
Spleen C1 neg. neg. V C1 C1
Ax.Ln. C1 C2 V V C1 neg.
Mes.Ln. C1 C2 neg. neg. C1 neg.
Cer.Ln. neg. neg. neg. neg. C1 neg.
Sub.Ln. neg. C2 V V C1 neg.
Retro.Ln. neg. neg. V V C1 neg.
Pal.T. neg. neg. V neg. C1 neg.
Ling.T. neg. neg. neg. neg. C1 neg.
Thymus C2 neg. neg. neg. neg. neg.
Note. At the time of necropsy, virus isolation was attempted from the indicated lymphatic tissues. Virus isolates were characterized by PCR as
described under Materials and Methods. C1: SIVmac239 challenge virus; C2: SHIV challenge virus; neg.: virus isolation negative. Ln.: lymph node;
Ax.: axillary; Mes.: mesenteric; Cer.: cerverical; Sub.: submandibular; Retro.: retropharyngeal; Pal. T.: palatine tonsil; Ling. T.: lingual tonsil.
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Polymerase chain reaction
To analyze the stability of SIV-IL4 and SIV-IFN,
CEMx174 cells infected with the different SIV variants
were lysed in buffer K (50 mM KCl, 15 mM Tris, 2.5 mM
MgCl2, 0.5% Tween 20, 100 g/ml Proteinase K). Using
the primers Sns and Sna, which flank the inserted cyto-
kine cDNAs, fragments were amplified from the lysates
under conditions previously described (Gundlach et al.,
2000). Virus isolates after the first challenge were also
characterized by PCR with the primers Sns and Sna.
Isolates were classified as challenge virus (C) if the
product had an approximate size of 672 bp or as vaccine
virus (V) if the PCR product was equal to or smaller than
the size of the PCR products obtained with SIV-IL4 or
SIV-IFN, respectively. After the second challenge three
different PCRs were performed to characterize the virus
isolates as described (Gundlach et al., 2000). The SIV
challenge virus (C1) was identified with the primers Ses
and na specific for the env gene of SIV and the nef
region deleted in SIV-IL4 and SIV-IFN, respectively. A
primer pair (Hes and Hea) specific for HIV-1 env was
used to identify SHIV (C2). The vaccine virus (V) was
identified by primers Sns and Sna as described above.
Quantitative RNA PCR was used to estimate the virus
load in plasma as previously described (ten Haaft et al.,
1998). Cytokine mRNA levels in the lymph nodes of in-
fected monkeys were also determined as previously de-
scribed (Zou et al., 1997).
Determination of cytokine activity
The IL-4 bioactivity was measured on Cth4S cells
essentially as described (Kinzer et al., 1994). One unit of
IL-4 was defined as the amount that gave the same
[H3]thymidine incorporation as one unit of a recombinant
IL-4 standard (Boehringer Mannheim, Mannheim, Ger-
many; specific activity: 500 U/g). The lower detection
limit of the assay was 2.5 units/ml. The IFN- bioactivity
was determined by the inhibition of encephalomyocardi-
tis virus (ECMV) induced cytopathic effects on Hep 2
cells. One unit of IFN- was defined as the amount that
inhibited ECMV induced Hep2 killing to the same extent
as one unit of recombinant IFN- (Boehringer Mannheim,
specific activity: 20,000 U/g). The lower detection limit
was 2.5 U/ml. Supernatants of uninfected and SIV-NU-
infected CEMx174 cells served as negative controls.
FACS analysis
Ficoll–Hypaque (d  1.077; Pharmacia, Freiburg, Ger-
many) gradient-isolated PBMC were phenotypically char-
acterized by employing three-color fluorescence analy-
sis on a FACScan flow cytometer (Becton-Dickinson,
Heidelberg, Germany) as described previously (Sopper
et al., 2000). The following antibodies were used in com-
bination with the anti-monkey CD3 antibody FN18 (M.
Jonker, BPRC, Rijswijk, The Netherlands; biotin-conju-
gated using standard techniques and detected with
streptavidin-coupled CyChrome from Pharmingen, Ham-
burg, Germany): CD20-FITC (B1, Coulter, Krefeld, Ger-
many) CD29-FITC (4B4, Coulter), CD4-PE (OKT4, Ortho,
Neckargemuend, Germany), CD8-FITC (RPAT8, Pharmin-
gen), and CD69-PE (Becton-Dickinson).
Statistical analysis
The Mann–Whitney U test was used to compare SIV-Env
and SIV-Gag antibody levels. For all other parameters the
two-tailed t test was performed using the SigmaStat
(version 2.03, SPSS Inc., San Rafael, CA) statistical soft-
ware package. Comparisons of the cell-associated viral
loads were made after logarithmic transformation of the
area under the curve during the first 2 months after
infection. Viral RNA levels 16 weeks after infection were
compared using the logarithmically transformed RNA
copy numbers of each animal. Comparisons of the anti-
body titers against whole-virus antigen at 22 weeks
postinfection were made after logarithmic transformation
of the reciprocal values of the titers.
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